A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried?

AbbVie's (NYSE: ABBV) financial results have been pretty strong lately. In its first-quarter update released on April 29, it generated $15 billion in revenue -- above its own guidance of $14.7 billion -- with the top line increasing 12.4% year over year. The drugmaker's shares jumped on the heels of its earnings release. AbbVie's immunology segment is currently doing the heavy lifting, with its two most important growth drivers, Skyrizi and Rinvoq, continuing to exceed expectations.But what if one of them encounters significant competition soon? That's what some investors believe might happen, given recent clinical progress by Oruka Therapeutics (NASDAQ: ORKA), a clinical-stage biotech. Is it time to worry about AbbVie's growth pillars?Image source: The Motley Fool.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool